Mirum Pharmaceuticals (MIRM) Return on Capital Employed (2019 - 2026)
Mirum Pharmaceuticals' quarterly Return on Capital Employed came in at 134.07% in Q1 2026, down 12026.0% year-on-year from N/an in Q1 2025, and down 3583.39% quarter-over-quarter from 3.64% in Q4 2025.
Mirum Pharmaceuticals has reported Return on Capital Employed for 8 years, with the latest figure at 134.07% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 12026.0% year-over-year to 134.07%; the trailing twelve-month figure through Mar 2026 stood at 134.07% (down 12026.0% YoY), and the FY2025 full-year result was 4.02%, up 1245.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 134.07%, down from 3.64% in the prior quarter.
- The five-year high for Return on Capital Employed was 3.64% in Q4 2025, with the low at 134.07% in Q1 2026.
- Average Return on Capital Employed over 5 years is 34.42%, with a median of 19.96% recorded in 2024.
- Year-over-year, Return on Capital Employed jumped 3521 bps in 2022 and sank 12026 bps in 2026.
- Tracing MIRM's Return on Capital Employed over 5 years: stood at 44.65% in 2022, then surged by 56 bps to 19.44% in 2023, then grew by 17 bps to 16.14% in 2024, then soared by 77 bps to 3.64% in 2025, then sank by 3583 bps to 134.07% in 2026.
- The last three Return on Capital Employed figures came in at 134.07% (Q1 2026), 3.64% (Q4 2025), and 7.02% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Mirum Pharmaceuticals | 5.97 Bn | 5.59 Bn | 131.08 Mn | -134.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134.07% |
| Dec 31, 2025 | -3.64% |
| Sep 30, 2025 | -7.02% |
| Jun 30, 2025 | -10.13% |
| Mar 31, 2025 | -13.80% |
| Dec 31, 2024 | -16.14% |
| Sep 30, 2024 | -17.49% |
| Jun 30, 2024 | -19.93% |
| Mar 31, 2024 | -19.96% |
| Dec 31, 2023 | -19.44% |
| Sep 30, 2023 | -23.44% |
| Jun 30, 2023 | -35.86% |
| Mar 31, 2023 | -42.68% |
| Dec 31, 2022 | -44.65% |
| Sep 30, 2022 | -51.05% |
| Jun 30, 2022 | -62.91% |
| Mar 31, 2022 | -62.95% |
| Dec 31, 2021 | -78.00% |
| Sep 30, 2021 | -86.26% |
| Jun 30, 2021 | -69.77% |
| Mar 31, 2021 | -66.08% |
| Dec 31, 2020 | -60.32% |
| Sep 30, 2020 | -66.14% |
| Jun 30, 2020 | -54.27% |
| Mar 31, 2020 | -48.28% |
| Dec 31, 2019 | -39.27% |